It's difficult for oncology clinical trials to identify and recruit patients for inclusion who have particular, relevant genomic tumor profiles. Startup Strata Oncology has launched with a $12 million Series A and a partnership with Thermo Fisher Scientific ($TMO) with the intention of enabling that process. It aims to offer free tumor sequencing to 100,000 cancer patients in the effort to help biopharma find the right patients for clinical trials.
Starting early next year, Strata aims to launch this massive effort to help characterize the mutations causing cancer. The Ann Arbor, MI-based company hopes to characterize a wide range of these mutations and to match patients with appropriate clinical trials. It expects to conduct the trial through more than 100 partner hospitals and cancer centers in the U.S. The first 50 sites are expected to be selected this year.